Evidence map›Paper›PMID 42733128›Full record

SynthesisClinical obesity2026

Weight Reduction Heterogenicity and Mediators of GLP-1RAs and Dual Agonists for Individuals With Obesity: A Meta-Analysis.

Difei Lu, Na Li, Zhenfang Yuan, Ying Gao

Abstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical obesity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Difei LuDepartment of Endocrinology, Peking University First Hospital, Beijing, China.ORCID https://orcid.org/0000-0003-3953-8900
Na LiDepartment of Endocrinology, Peking University First Hospital, Beijing, China.
Zhenfang YuanDepartment of Endocrinology, Peking University First Hospital, Beijing, China.
Ying GaoDepartment of Endocrinology, Peking University First Hospital, Beijing, China.ORCID https://orcid.org/0000-0002-9156-9483

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual agonists have become pivotal options for obesity, but marked weight loss heterogeneity remains poorly understood. This meta-regression analysis aimed to identify factors influencing this heterogeneity. We searched Medline, Embase, The Cochrane Library, and Web of Science up to February 1, 2026, enrolling 32 eligible trials (40 408 participants) following PRISMA guidelines. Meta-regression and subgroup analyses were performed using R software. Pooled analysis showed that GLP-1RAs and dual agonists achieved a weighted mean weight reduction of 9.36% (95% CI 7.92%-10.80%), with high interstudy heterogeneity (I

Indexed as

Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsObesityWeight LossDiabetes Mellitus, Type 2HumansTirzepatideAnti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsTirzepatideglucagon‐like peptide‐1 receptor agonistsmeta‐regressiontirzepatideweight reduction

Identifiers

PMID42733128
PMCPMC13572569

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.